Till Milde

Standard treatment against paediatric BRAF-V600E glioma promotes senescence and sensitizes tumours to BCL-xL inhibition

This study shows that standard therapies for paediatric BRAF-V600E glioma induce senescence, which can be targeted by BCL-xL inhibitors to prevent tumour regrowth.

The ITCC-P4 PDX platform of pediatric cancers for preclinical testing

The paper introduces a PDX platform for pediatric cancers, providing in vivo drug testing models and molecular data to aid in therapy development.

O-mannosylation and protein maturation check-points represent therapeutic opportunities in BRAF fusion protein oncogenesis

The paper identifies O-mannosylation and protein maturation as therapeutic targets in BRAF fusion oncogenesis by showing their necessity for fusion-induced transformation.

Medulloblastoma oncogene aberrations are not involved in tumor initiation, but essential for disease progression and therapy resistance

The paper uses single-cell technologies to show that large-scale chromosomal aberrations drive medulloblastoma initiation, while single-gene oncogenic events like MYC contribute to progression and therapy resistance.

Cell-state plasticity drives heterogeneity in Group 3/4 medulloblastoma

This study identifies cell-state plasticity as a driver of heterogeneity in Group 3/4 medulloblastomas, showing that transcription factor perturbation can redirect tumor cells along different differentiation trajectories.

Integrated phospho-proteogenomic and single-cell transcriptomic analysis of meningiomas establishes robust subtyping and reveals subtype-specific immune invasion

This study integrates phospho-proteogenomic and single-cell transcriptomic data to subtype meningiomas and identify subtype-specific immune infiltration patterns.

Distribution of GOPC:ROS1 and other ROS1 fusions in glioma types

The paper identifies ROS1 fusions in various glioma types through genomic and transcriptomic analysis, showing they are not restricted to specific subtypes.